Abstract: A polypeptide drug conjugate, a compound represented by formula (V) and an application thereof are provided.

Abstract: A tricyclic polypeptide conjugated drug and the use thereof are provided. Specifically provided are a compound as represented by formula (III), and a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of the compound or the pharmaceutically acceptable salt thereof is further provided. The compound or the pharmaceutically acceptable salt thereof and the pharmaceutical composition can be used in the preparation of a drug for treating Nectin-4 overexpressed solid tumors.

Abstract: The present application relates to a 2,3-dihydro-1H-pyrrolizine-7-formamide derivative as a nucleoprotein inhibitor and a use in preparation of a drug for treating HBV related diseases. The present application specifically relates to a compound represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

Abstract: A pharmaceutical combination containing a capsid protein inhibitor and a nucleoside analog, selected from entecavir or a pharmaceutically acceptable salt thereof or a solvate thereof, or tenofovir or a pharmaceutically acceptable salt or pharmaceutically acceptable prodrug thereof, as well as a use of said pharmaceutical combination in treating a hepatitis B virus infection. The pharmaceutical combination has a good hepatitis B virus infection-fighting effect.

Abstract: A compound having a KHK inhibitory effect, or pharmaceutically acceptable salts thereof, and use thereof in the preparation of a medicament for treating a disease associated with KHK kinase abnormal expression. Provided is a compound as represented by formula (III) or a pharmaceutically acceptable salt thereof.

Abstract: A crystal form of a compound of formula (I), a hydrate thereof, a solvate thereof, or a co-complex of water and a solvent, and the use thereof in the preparation of a drug for treating a disease associated with HBV.

Abstract: A class of compounds that have a pyrazine structure, specifically disclosed is a compound represented by formula, isomers or pharmaceutically acceptable salts thereof, and an application thereof in the preparation of CRAC inhibitors.

Abstract: The present application relates to a 2,3-dihydro-1H-pyrrolizine-7-formamide derivative as a nucleoprotein inhibitor and a use in preparation of a drug for treating HBV related diseases. The present application specifically relates to a compound represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

Abstract: The present invention provides a salt and crystal form of a modified andrographolide compound and a preparation method and pharmaceutical use thereof.

Abstract: The present disclosure provides a filter material used for automobile air conditioning and capable of filtering out volatile organic compound (VOC) gas, including a sandwich structure (100) and an activated carbon fiber (ACF) non-woven fabric layer (200) located at one side of the sandwich structure (100), where, the ACF non-woven fabric layer (200) is composed of interleaved ACFs, and the ACF non-woven fabric layer (200) is compounded with the sandwich structure (100) via hot melt adhesive (HMA) (210).

Abstract: The present invention provides a salt and crystal form of a modified andrographolide compound and a preparation method and pharmaceutical use thereof.

Abstract: The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.

Abstract: Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.

Abstract: This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.

Abstract: The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.

Abstract: This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.